(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.24%) $79.14
(0.10%) $2.04
(0.18%) $2 313.70
(0.36%) $26.93
(0.09%) $963.50
(-0.14%) $0.932
(-0.42%) $10.98
(-0.13%) $0.797
(-2.30%) $91.12
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 11.77%
Live Chart Being Loaded With Signals
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases...
Stats | |
---|---|
Šios dienos apimtis | 326 243 |
Vidutinė apimtis | 403 480 |
Rinkos kapitalizacija | 66.08M |
EPS | $0 ( 2024-03-12 ) |
Kita pelno data | ( $-0.190 ) 2024-06-27 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.620 |
ATR14 | $0.0220 (2.68%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Mcclure Matthew W. | Buy | 72 000 | Stock Option (Right to Buy) |
2024-03-01 | Calhoun Lesley Ann | Buy | 308 940 | Stock Option (Right to Buy) |
2024-03-01 | Symons Julian A. | Buy | 72 000 | Stock Option (Right to Buy) |
2024-03-01 | Blatt Lawrence | Buy | 965 435 | Stock Option (Right to Buy) |
2024-02-28 | Hirth Peter | Buy | 4 411 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
82.23 |
Last 96 transactions |
Buy: 18 924 669 | Sell: 1 675 487 |
Tūris Koreliacija
Aligos Therapeutics, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MCRB | 0.914 |
EIGR | 0.914 |
SPRC | 0.908 |
BTTX | 0.907 |
ENTA | 0.907 |
CYN | 0.906 |
AFIB | 0.906 |
CAMP | 0.905 |
GOCO | 0.904 |
MESA | 0.904 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
GEEX | -0.92 |
FXCO | -0.918 |
LDHA | -0.917 |
NESR | -0.914 |
TCVA | -0.911 |
ALOR | -0.911 |
TBSA | -0.909 |
VLAT | -0.909 |
AHRN | -0.908 |
LGAC | -0.908 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Aligos Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos
Aligos Therapeutics, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $15.53M |
Bruto pelnas: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2023 |
Pajamos: | $15.53M |
Bruto pelnas: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2022 |
Pajamos: | $13.91M |
Bruto pelnas: | $10.23M (73.57 %) |
EPS: | $-2.25 |
FY | 2021 |
Pajamos: | $4.36M |
Bruto pelnas: | $4.36M (100.00 %) |
EPS: | $-3.22 |
Financial Reports:
No articles found.
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.